EUR 0.03
(25.0%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -0.00 EUR | 100.0% |
2022 | -117.60 EUR | 99.75% |
2021 | -47.56 Thousand EUR | 93.48% |
2020 | -729.37 Thousand EUR | 80.96% |
2019 | -3.83 Million EUR | 64.47% |
2018 | -10.78 Million EUR | 37.12% |
2017 | -17.14 Million EUR | 32.23% |
2016 | -25.29 Million EUR | -1781462.87% |
2015 | -1419.87 EUR | 55.38% |
2014 | -3182.07 EUR | 5.97% |
2013 | -3384.09 EUR | 21.34% |
2012 | -4302.15 EUR | 12.25% |
2011 | -4902.74 EUR | 99.95% |
2010 | -8.98 Million EUR | -30.37% |
2009 | -6.89 Million EUR | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -3.32 EUR | 0.0% |
2023 Q2 | -3.06 EUR | 0.0% |
2023 FY | - EUR | 100.0% |
2023 Q4 | -0.00 EUR | 0.0% |
2022 Q2 | -1607.61 EUR | 0.0% |
2022 Q4 | - EUR | 0.0% |
2022 FY | - EUR | 99.75% |
2021 FY | - EUR | 93.48% |
2021 Q2 | - EUR | 0.0% |
2021 Q4 | - EUR | 0.0% |
2020 Q2 | -2.82 Million EUR | 0.0% |
2020 Q4 | - EUR | 0.0% |
2020 FY | - EUR | 80.96% |
2019 Q2 | -2.09 Million EUR | 0.0% |
2019 Q4 | -1.92 Million EUR | 0.0% |
2019 FY | - EUR | 64.47% |
2018 FY | - EUR | 37.12% |
2018 Q4 | -2.92 Million EUR | 0.0% |
2018 Q2 | -5.35 Million EUR | 0.0% |
2017 Q2 | -12.44 Million EUR | 0.0% |
2017 FY | - EUR | 32.23% |
2017 Q4 | -7.75 Million EUR | 0.0% |
2016 Q2 | - EUR | 0.0% |
2016 FY | - EUR | -1781462.87% |
2016 Q4 | - EUR | 0.0% |
2015 FY | - EUR | 55.38% |
2015 Q4 | - EUR | 0.0% |
2015 Q2 | - EUR | 0.0% |
2014 Q2 | - EUR | 0.0% |
2014 Q4 | - EUR | 0.0% |
2014 FY | - EUR | 5.97% |
2013 Q2 | -18.52 Thousand EUR | -90.67% |
2013 Q1 | -9717.38 EUR | 0.0% |
2013 FY | - EUR | 21.34% |
2013 Q4 | -15.27 Thousand EUR | -57.22% |
2013 Q3 | -9717.38 EUR | 47.55% |
2012 Q1 | -10.74 Thousand EUR | 0.0% |
2012 Q4 | -9717.38 EUR | 9.57% |
2012 Q3 | -10.74 Thousand EUR | 0.0% |
2012 FY | - EUR | 12.25% |
2012 Q2 | -10.74 Thousand EUR | 0.0% |
2011 Q2 | -17.02 Thousand EUR | 0.0% |
2011 Q3 | -17.02 Thousand EUR | 0.0% |
2011 Q4 | -10.74 Thousand EUR | 36.89% |
2011 FY | - EUR | 99.95% |
2011 Q1 | -17.02 Thousand EUR | 0.0% |
2010 Q2 | -16.39 Thousand EUR | 0.0% |
2010 Q3 | -16.39 Thousand EUR | 0.0% |
2010 Q4 | -17.02 Thousand EUR | -3.88% |
2010 Q1 | -16.39 Thousand EUR | 0.0% |
2010 FY | - EUR | -30.37% |
2009 Q3 | -12.57 Thousand EUR | 0.0% |
2009 Q1 | -12.57 Thousand EUR | 0.0% |
2009 FY | - EUR | 0.0% |
2009 Q2 | -12.57 Thousand EUR | 0.0% |
2009 Q4 | -16.39 Thousand EUR | -30.37% |
2008 Q4 | -12.57 Thousand EUR | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
ABIONYX Pharma SA | -0.12 EUR | 97.917% |
ABIVAX Société Anonyme | -3.43 EUR | 99.927% |
Adocia SA | -1.91 EUR | 99.869% |
Aelis Farma SA | -0.39 EUR | 99.359% |
Biophytis S.A. | -12.55 EUR | 99.98% |
Advicenne S.A. | -0.67 EUR | 99.627% |
genOway Société anonyme | 0.17 EUR | 101.471% |
IntegraGen SA | -0.03 EUR | 90.347% |
Medesis Pharma S.A. | -0.80 EUR | 99.688% |
NFL Biosciences SA | -0.46 EUR | 99.457% |
Plant Advanced Technologies SA | 0.07 EUR | 103.571% |
Quantum Genomics Société Anonyme | -0.09 EUR | 97.253% |
Sensorion SA | -0.17 EUR | 98.529% |
Theranexus Société Anonyme | -0.88 EUR | 99.716% |
TME Pharma N.V. | -1.34 EUR | 99.813% |
Valbiotis SA | -0.59 EUR | 99.576% |
TheraVet SA | -0.49 EUR | 99.49% |
Valerio Therapeutics Société anonyme | -0.15 EUR | 98.333% |
DBV Technologies S.A. | -0.71 EUR | 99.648% |
Genfit S.A. | -0.58 EUR | 99.569% |
GeNeuro SA | -0.59 EUR | 99.576% |
Innate Pharma S.A. | -0.09 EUR | 97.343% |
Inventiva S.A. | -2.43 EUR | 99.897% |
MaaT Pharma SA | -1.73 EUR | 99.855% |
MedinCell S.A. | -0.88 EUR | 99.716% |
Nanobiotix S.A. | -1.08 EUR | 99.769% |
OSE Immunotherapeutics SA | -1.18 EUR | 99.788% |
Poxel S.A. | -0.91 EUR | 99.725% |
GenSight Biologics S.A. | -0.54 EUR | 99.537% |
Transgene SA | -0.22 EUR | 98.864% |
Valneva SE | -0.73 EUR | 99.658% |